Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 801–900 of 15,747
Dhakal, B., Abedin, S. M., Fenske, T. S., Chhabra, S., Ledeboer, N. A., Hari, P., & Hamadani, M. (2021) · Blood · doi:10.1182/blood.2021012769 · Cited by 126
SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review
Fathizadeh, H., Afshar, S., Masoudi, M. R., Gholizadeh, P., Asgharzadeh, M., Ganbarov, K., Köse, Ş., Yousefi, M., & Kafil, H. S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.08.076 · Cited by 139
“Pfizer and BioNTech have also developed several RNA-based vaccines that have been successful in clinical trials and are now being used in many countries [49,92].”
Emerging vaccine nanotechnology: From defense against infection to sniping cancer
Feng, C., Li, Y., Ferdows, B. E., Patel, D. N., Ouyang, J., Tang, Z., Kong, N., Chen, E., & Tao, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.021 · Cited by 140
BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
Alghamdi, A. N., Alotaibi, M. I., Alqahtani, A. S., Aboud, D. A., & Abdel-Moneim, A. S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.760047 · Cited by 134
“This finding agrees with the data of phase 2/3 clincal trial that reported 88% pain at the site of injection following vaccination with ChAdOx1 (25), in individuals 18–55 of age and it reached >80% in individuals (≥16 years old) vaccinated with BNT162b2 (23).”
ResultImmunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Geers, D., Schmitz, K. S., Garcia Garrido, H. M., Koopmans, M. P. G., Dalm, V. A. S. H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116747 · Cited by 124
Hewavisenti, R., Arena, J., Ahlenstiel, C., & Sasson, S. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112513 · Cited by 165
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
Boettler, T., Csernalabics, B., Salié, H., Luxenburger, H., Wischer, L., Alizei, E. S., Zoldan, K., Krimmel, L., Bronsert, P., Schwabenland, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.040 · Cited by 131
“A 52-year old male and 3 health care workers (all HLA-A*03:01, confirmed by NGS) >26 days post boost (dpb) vaccination who received the mRNA vaccine BNT162b2 were recruited at the University Medical Center Freiburg, Germany.”
MethodInfluentialNanishi, E., Borriello, F., O’Meara, T. R., McGrath, M. E., Saito, Y., Haupt, R. E., Seo, H., van Haren, S. D., Cavazzoni, C. B., Brook, B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5305 · Cited by 129
Xu, S., Huang, R., Sy, L. S., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7043e2 · Cited by 123
Translational medicine for acute lung injury
Zhang, J., Guo, Y., Mak, M., & Tao, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04828-7 · Cited by 148
“LNP-encapsulated mRNA-based vaccines encoding SARS-CoV-2 spike proteins demonstrated significant efficacy in preventing viral infection, reducing the severity of COVID-19 illness, and lowering COVID-related mortality [175, 176].”
BackgroundTerpos, E., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Briasoulis, Α., Gumeni, S., Malandrakis, P., Fotiou, D., Papanagnou, E., Migkou, M., Theodorakakou, F., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00530-3 · Cited by 127
Kaplonek, P., Fischinger, S., Cizmeci, D., Bartsch, Y. C., Kang, J., Burke, J. S., Shin, S. A., Dayal, D., Martin, P., Mann, C., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.001 · Cited by 121
“However, protection from infection has been observed: (1) just weeks after primary mRNA and Ad26 immunization prior to the induction of neutralizing antibodies (Stephenson et al., 2021; Polack et al., 2020); (2) in regions of the world where the vaccine neutralizes the variants poorly (Alter et al.”
Covid-19 vaccination in pregnancy
Badell, M. L., Dude, C. M., Rasmussen, S. A., & Jamieson, D. J. (2022) · BMJ · doi:10.1136/bmj-2021-069741 · Cited by 148
Aggarwal, A., Stella, A. O., Walker, G., Akerman, A., Esneau, C., Milogiannakis, V., Burnett, D. L., McAllery, S., Silva, M. R., Lu, Y., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01135-7 · Cited by 121
Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S. R., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq1945 · Cited by 122
“Thus, in addition to mRNA-N, we also generated an m1-modified mRNA vaccine that expresses the prefusion-stabilized SARS-CoV-2 S protein with two proline mutations (named “mRNA-S-2P”; Wuhan-Hu-1), similar to Pfizer/ BioNTech’s BNT162b (37) and Moderna’s mRNA-1273 (38) vaccines.”
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
Vicenti, I., Zazzi, M., & Saladini, F. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1880568 · Cited by 132
Impact of COVID-19 on Cardiovascular Disease
Vosko, I., Zirlik, A., & Bugger, H. (2023) · Viruses · doi:10.3390/v15020508 · Cited by 158
Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19
Hammerman, A., Sergienko, R., Friger, M., Beckenstein, T., Peretz, A., Netzer, D., Yaron, S., & Arbel, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119497 · Cited by 133
Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery
Feng, C., Shi, J., Fan, Q., Wang, Y., Huang, H., Chen, F., Tang, G., Li, Y., Li, P., Li, J. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25312-0 · Cited by 126
Self-citationAssociation of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study
Shemer, A., Pras, E., Einan-Lifshitz, A., Dubinsky-Pertzov, B., & Hecht, I. (2021) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2021.1259 · Cited by 121
Becerril‐Gaitan, A., Vaca‐Cartagena, B. F., Ferrigno, A. S., Mesa-Chávez, F., Barrientos‐Gutiérrez, T., Tagliamento, M., Lambertini, M., & Villarreal-Garza, C. M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.014 · Cited by 129
“cacy of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines’ in preventing COVID-19 among the general population [15,16], data about their performance in oncological patients remain scarce.”
Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
Rodríguez-Jiménez, P., Chicharro, P., Cabrera, L.-M., Seguí, M., Morales-Caballero, Á., Llamas-Velasco, M., & Sánchez-Pérez, J. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.04.014 · Cited by 122
“However, the adverse event reporting method did not specify the type of adverse event but just the severity.(4) Patients receiving the BNT162b2 mRNA COVID19 vaccine apparently do not suffer from lymphopenia and do not have symptoms suggesting cytokine release.”
MethodPhylactou, M., Li, J.-P. O., & Larkin, F. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319338 · Cited by 121
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K.-K., Wang, H., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103904 · Cited by 120
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 133
“On the contrary, B.1.1.7 is neutralized by sera from BNT162b2 without reducing antibody neutralization efficacy [46,160].”
BackgroundInfluentialSanders, J.-S. F., Bemelman, F. J., Messchendorp, A. L., Baan, C. C., van Baarle, D., van Binnendijk, R., Diavatopoulos, D. A., Frölke, S. C., Geers, D., GeurtsvanKessel, C. H., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000003983 · Cited by 188
Triantafyllidis, K. K., Giannos, P., Tariq-Mian, I., Kyrtsonis, G., & Kechagias, K. S. (2021) · Vaccines · doi:10.3390/vaccines9091013 · Cited by 131
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
Cobey, S. E., Larremore, D. B., Grad, Y. H., & Lipsitch, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00544-9 · Cited by 125
Liew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N. A., Siggins, M. K., Swieboda, D. P., Sidhu, J. K., Efstathiou, C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104402 · Cited by 131
RNA therapeutics: updates and future potential
Zhang, C., & Zhang, B. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2171-2 · Cited by 131
“Furthermore, the favorable safety profile was also confirmed in this study, where reactogenicity events, such as fatigue, systemic reactions, and lymphadenopathy, resolved on its own within a few days of onset (Polack et al., 2020).”
BackgroundA look into the future of the COVID-19 pandemic in Europe: an expert consultation [viewpoint].
Iftekhar, E. N., Priesemann, V., Balling, R., Bauer, S., Beutels, P., Valdez, A. S. C., Cuschieri, S., Czypionka, T., Dumpis, U., Glaab, E., et al. (2021) · BORIS (University Library Bern) · doi:10.17863/cam.75145 · Cited by 119
He, L., Lin, X., Wang, Y., Abraham, C., Sou, C., Ngo, T., Zhang, Y., Wilson, I. A., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abf1591 · Cited by 122
Tande, A. J., Pollock, B. D., Shah, N. D., Farrugia, G., Virk, A., Swift, M., Breeher, L., Binnicker, M., & Berbari, E. F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab229 · Cited by 120
Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., & Zepp, F. (2021) · Vaccines · doi:10.3390/vaccines9040390 · Cited by 147
Fan, Y.-J., Chan, K.-H., & Hung, I. F.-N. (2021) · Vaccines · doi:10.3390/vaccines9090989 · Cited by 119
“, 2020 [22] low high low low low low low”
BackgroundBeaudoin-Bussières, G., Chen, Y., Ullah, I., Prévost, J., Tolbert, W. D., Symmes, K., Ding, S., Benlarbi, M., Gong, S. Y., Tauzin, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110368 · Cited by 127
“Several vaccine platforms have been approved in different jurisdictions worldwide to counter the COVID-19 pandemic (Oliver et al., 2021a, 2021b; Polack et al., 2020; Voysey et al., 2021) with vaccine development primarily focused on generating immune responses against the SARS-CoV-2 spike.”
BackgroundKing, R. G., Silva-Sánchez, A., Peel, J. N., Botta, D., Dickson, A. M., Pinto, A. K., Meza‐Perez, S., Allie, S. R., Schultz, M. D., Liu, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9080881 · Cited by 141
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023
Tervaert, J. W. C., Martínez‐Lavín, M., Jara, L. J., Halpert, G., Watad, ., Amital, H., & Shoenfeld, Y. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103287 · Cited by 146
Friedman, M., Curtis, J. R., & Winthrop, K. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221244 · Cited by 137
Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz‐Foumani, R., Kolahi, A., Singh, K., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2318 · Cited by 125
“Most of the reported adverse events were non‐serious local or systemic reactions, such as injection site pain, erythema, swelling, fever, headache and myalgia.(6) However, a wide range of adverse events and complications have been reported for mRNA‐ based COVID‐19 vaccines, which can affect the nervous and cardiovascu…”
BackgroundMyocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines
Shay, D. K., Shimabukuro, T. T., & DeStefano, F. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2821 · Cited by 118
Wismans, A., Thurik, R., Baptista, R., Dejardin, M., Janssen, F., & Franken, I. H. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255382 · Cited by 144
“Since effective vaccines against COVID-19 have been developed [1, 2], the greatest challenge is to ensure sufficiently high vaccination rates to PLOS ONE”
BackgroundCOVID-19 Vaccine Hesitancy among Young Adults in Saudi Arabia: A Cross-Sectional Web-Based Study
Almaghaslah, D., Alsayari, A., Kandasamy, G., & Vasudevan, R. (2021) · Vaccines · doi:10.3390/vaccines9040330 · Cited by 118
Goepfert, P. A., Fu, B., Chabanon, A.-L., Bonaparte, M. I., Davis, M. G., Essink, B. J., Frank, I., Haney, O., Janosczyk, H., Keefer, M. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00147-x · Cited by 117
Li, X., Raventós, B., Roel, E., Pistillo, A., Martinez-Hernandez, E., Delmestri, A., Reyes, C., Strauss, V., Prieto-Alhambra, D., Burn, E., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068373 · Cited by 118
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older
Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y.-J., Lewin, B., & Lee, M.-S. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5511 · Cited by 117
Nir, O., Schwartz, A., Toussia‐Cohen, S., Leibovitch, L., Strauss, T., Asraf, K., Doolman, R., Sharabi, S., Cohen, C., Lustig, Y., et al. (2021) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2021.100492 · Cited by 122
“The novel BNT162b2 messenger RNA (mRNA) vaccine against SARS-CoV-2 was shown to be effective both in a randomized trial and in a nationwide mass vaccination setting, yet pregnant and lactating women were excluded from all clinical trials.(2,3) Vaccination recommendations during pregnancy differ greatly around the glob…”
Samanovic, M. I., Cornelius, A. R., Gray-Gaillard, S. L., Allen, J. R., Karmacharya, T., Wilson, J. P., Hyman, S. W., Tuen, M., Koralov, S. B., Mulligan, M. J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi8961 · Cited by 117
Yang, J., Marziano, V., Deng, X., Guzzetta, G., Zhang, J., Trentini, F., Cai, J., Poletti, P., Zheng, W., Wang, W., et al. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01155-z · Cited by 122
Sacco, C., Manso, M. D., Mateo‐Urdiales, A., Rota, M. C., Petrone, D., Riccardo, F., Bella, A., Siddu, A., Battilomo, S., Proietti, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01185-0 · Cited by 121
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Tiboni, M., Casettari, L., & Illum, L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120686 · Cited by 128
Yang, Z., Liu, Y., Zhao, K., Jing, W., Gao, L., Dong, X., Wang, Y., Han, M., Shi, C., Tang, C., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.021 · Cited by 133
Uversky, V. N., Redwan, E. M. M. M., Makis, W., & Rubio‐Casillas, A. (2023) · Vaccines · doi:10.3390/vaccines11050991 · Cited by 145
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza
Chivukula, S., Plitnik, T., Tibbitts, T., Karve, S., Dias, A., Zhang, D., Goldman, R., Gopani, H., Khanmohammed, A., Sarode, A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00420-6 · Cited by 117
Self-citationCOVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
He, Q., Mao, Q., Zhang, J., Bian, L., Gao, F., Wang, J., Xu, M., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669339 · Cited by 117
Resurgence of SARS-CoV-2: Detection by community viral surveillance
REACT study group, Riley, S., Ainslie, K. E. C., Eales, O. D., Walters, C. E., Wang, H., Atchison, C. J., Fronterrè, C., Diggle, P. J., Ashby, D., et al. (2021) · Science · doi:10.1126/science.abf0874 · Cited by 122
COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts
Rashedi, R., Samieefar, N., Masoumi, N., Mohseni, S., & Rezaei, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27463 · Cited by 136
To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination
Chiu, N., Chi, H., Tu, Y., Huang, Y.-N., Tai, Y., Weng, S.-L., Chang, L., Huang, D. T., Huang, F.-Y., & Lin, C. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1971522 · Cited by 121
“The BNTspecific two-proline mutation of the spike protein may further elicit stronger neutralizing responses [7,41].”
BackgroundOccurrence of severe COVID-19 in vaccinated transplant patients
Caillard, S., Chavarot, N., Bertrand, D., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.011 · Cited by 116
“Although mRNA-based vaccines elicit a strong immune response in the general population, the immunization rates of immunocompromised patients—including solid organ transplant recipients—have not been specifically investigated in mRNA-1273 and BNT162b2 pivotal trials.(1,2) This knowledge gap should be addressed urgently…”
BackgroundCOVID-19 vaccines and kidney disease
Windpessl, M., Bruchfeld, A. N., Anders, H., Kramer, H., Waldman, M. A., Rénia, L., Ng, L. F. P., Xing, Z., & Kronbichler, A. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00406-6 · Cited by 120
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Rolfes, L., Pawlitzki, M., Pfeuffer, S., Nelke, C., Lux, A., Pul, R., Kleinschnitz, C., Kleinschnitz, K., Rogall, R., Pape, K., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001035 · Cited by 124
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
Winokur, P., Gayed, J., Fitz-Patrick, D., Thomas, S. J., Diya, O., Lockhart, S., Xu, X., Zhang, Y., Bangad, V., Schwartz, H. I., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213082 · Cited by 116
Self-citationKrammer, F., Srivastava, K., the PARIS team, & Simon, V. (2021) · doi:10.1101/2021.01.29.21250653 · Cited by 116
Respiratory viral infections in the elderly
Watson, A., & Wilkinson, T. M. A. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466621995050 · Cited by 133
Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals
(2021) · doi:10.1101/2021.02.16.21251535 · Cited by 335
Gushchin, V. А., Dolzhikova, I. V., Shchetinin, A. M., Odintsova, A. S., Siniavin, A. E., Nikiforova, M. A., Pochtovyi, A. A., Shidlovskaya, E. V., Kuznetsova, N. A., Burgasova, O., et al. (2021) · Vaccines · doi:10.3390/vaccines9070779 · Cited by 121
Rahman, M. M., Masum, M. H. U., Wajed, S., & Talukder, A. (2022) · VirusDisease · doi:10.1007/s13337-022-00755-1 · Cited by 127
“5% effective within seven days interval of two-dose vaccination [70, 97].”
BackgroundResultInfluentialVaccination in patients with kidney failure: lessons from COVID-19
Babel, N., Hugo, C., & Westhoff, T. H. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00617-5 · Cited by 129
(2021) · doi:10.1016/j.vaccine.2021.04.002 · Cited by 101
Hildreth, J. E. K., & Alcendor, D. J. (2021) · Vaccines · doi:10.3390/vaccines9050489 · Cited by 130
“These adverse events were more common in younger participants and occurred more frequently after the second dose [22,23].”
BackgroundInfluentialDuration of immune protection of SARS-CoV-2 natural infection against reinfection
Chemaitelly, H. S., Nagelkerke, N. J. D., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Kanaani, Z. A., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac109 · Cited by 114
Ciabattini, A., Pastore, G., Fiorino, F., Polvere, J., Lucchesi, S., Pettini, E., Auddino, S., Rancan, I., Durante, M., Miscia, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740708 · Cited by 121
“Two recent studies of BNT162b2 vaccine effectiveness against SARS-CoV-2 infection and COVID-19 cases, in a nationwide mass vaccination setting, demonstrate that the vaccine is effective for a wide range of COVID-19 related outcomes, such as hospitalization, severe illness, and death (3, 4) confirming data of effective…”
BackgroundVaccinations and Autoimmune Diseases
Olivieri, B., Betterle, C., & Zanoni, G. (2021) · Vaccines · doi:10.3390/vaccines9080815 · Cited by 133
Development of mRNA Vaccines: Scientific and Regulatory Issues
Knezevic, I., Liu, M. A., Peden, K., Zhou, T., & Kang, H.-N. (2021) · Vaccines · doi:10.3390/vaccines9020081 · Cited by 114
“Two mRNA vaccines have demonstrated around 95% efficacy in Phase 3 clinical trials [5,6] and have recently been approved for emergency use by national regulatory authorities in some countries to combat the pandemic [7,8].”
BackgroundHall, V. G., Ferreira, V. H., Wood, H., Ierullo, M., Majchrzak-Kita, B., Manguiat, K., Robinson, A., Kulasingam, V., Humar, A., & Kumar, D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01126-6 · Cited by 114
Broseta, J. J., Rodríguez‐Espinosa, D., Rodríguez, N., Mosquera, M., Marcos, M. Á., Egri, N., Pascal, M., Soruco, E., Bedini, J. L., Bayés, B., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.06.002 · Cited by 118
“those vaccinated.(15,16) Routine data have suggested these vaccines prevent 94% of symptomatic COVID-19 cases, 85% to 87% of hospital admissions, and 92% of severe disease.”
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
(2021) · doi:10.1038/s41467-021-27410-5 · Cited by 117
Intention to receive a COVID-19 vaccine: results from a population-based survey in Canada
Ogilvie, G. S., Gordon, S., Smith, L., Albert, A., Racey, C. S., Booth, A., Gottschlich, A., Goldfarb, D. A., Murray, M. C. M., Galea, L. A. M., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-11098-9 · Cited by 123
Levi, R., Azzolini, E., Pozzi, C., Ubaldi, L., Lagioia, M., Mantovani, A., & Rescigno, M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149154 · Cited by 113
Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective
Niebel, D., Novak, N., Wilhelmi, J., Ziob, J., Wilsmann‐Theis, D., Bieber, T. R. M., Wenzel, J., & Braegelmann, C. (2021) · Vaccines · doi:10.3390/vaccines9090944 · Cited by 123
“BNT162b2 Tozinameran, Comirnaty (BioNTech/Pfizer) mRNA December 2020 in UK >10%: Fatigue, headache, musculoskeletal pain, fever [4] 1–10%: Local injection site reaction: erythema, swelling; <1%: delayed local reactions (“COVID-arm”), morbilliform rash, urticarial reactions, pityriasis rosea; singular cases: Rowell’s s…”
BackgroundPotential neutralizing antibodies discovered for novel corona virus using machine learning
Magar, R., Yadav, P., & Barati Farimani, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-84637-4 · Cited by 114
Lozano-Ojalvo, D., Camara, C., Lopez-Granados, E., Nozal, P., del Pino-Molina, L., Bravo-Gallego, L. Y., Paz-Artal, E., Pion, M., Correa-Rocha, R., Ortiz, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109570 · Cited by 114
SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies
Almehdi, A. M., Khoder, G., Alchakee, A., Alsayyid, A. T., Sarg, N. H., & Soliman, S. S. M. (2021) · Infection · doi:10.1007/s15010-021-01677-8 · Cited by 123
“The results have shown that BNT162b2 was 95% effective in preventing COVID-19 infection [78].”
BackgroundMethodOng, E., Cooke, M. F., Huffman, A., Xiang, Z., Wong, M. U., Wang, H., Seetharaman, M., Valdez, N., & He, Y. O. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab279 · Cited by 132
“The S protein is the primary target of most COVID-19 vaccines, including the Pfizer (16) and Moderna (17) mRNA vaccines with high reported efficacy in Phase 3 clinical trials.”
BackgroundMachine Learning for Designing Next-Generation mRNA Therapeutics
Castillo-Hair, S. M., & Seelig, G. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00621 · Cited by 113
Connolly, C. M., Ruddy, J. A., Boyarsky, B. J., Barbur, I., Werbel, W. A., Geetha, D., Garonzik‐Wang, J., Segev, D. L., Christopher‐Stine, L., & Paik, J. J. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41924 · Cited by 121
“Participants reported systemic events (particularly myalgia and fatigue) at higher frequencies than in clinical trials; similar to the trials, reactogenicity increased after dose 2 (5,6).”
BackgroundResultInfluentialPrevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)
Gatt, D., Martin, I., AlFouzan, R., & Moraes, T. J. (2023) · Pathogens · doi:10.3390/pathogens12020154 · Cited by 146
Ly, H. H., Daniel, S., Soriano, S. K. V., Kis, Z., & Blakney, A. K. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00032 · Cited by 125
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Bertoletti, A., Bert, N. L., & Tan, A. T. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.008 · Cited by 131
Garcia-Grimshaw, M. A., Ceballos‐Liceaga, S. E., Hernández‐Vanegas, L. E., Núñez, I., Hernández-Valdivia, N., Carrillo-García, D. A., Michel‐Chávez, A., Galnares‐Olalde, J. A., Carbajal‐Sandoval, G., Saniger‐Alba, M. D. M., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108786 · Cited by 118
mRNA vaccines for COVID-19 and diverse diseases
Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 132
“Overall, 95% efficacy (Table 3) was shown by BNT162b2 in preventing COVID-19, while 90–100% was recorded across subgroups defined by ethnicity, BMI, age, sex as well as co-existing conditions [154].”
Manothummetha, K., Chuleerarux, N., Sanguankeo, A., Kates, O. S., Hirankarn, N., Thongkam, A., Dioverti, M. V., Torvorapanit, P., Langsiri, N., Worasilchai, N., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.6822 · Cited by 121
Goldman, J. D., Robinson, P. C., Uldrick, T. S., & Ljungman, P. T. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002630 · Cited by 122
SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting
Butt, A. A., Omer, S. B., Yan, P., Shaikh, O. S., & Mayr, F. B. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1577 · Cited by 109
Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety
Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112
(2021) · doi:10.1371/journal.pmed.1003769 · Cited by 111
Herpes zoster emergence following mRNA COVID‐19 vaccine
Eid, E., Abdullah, L., Kurban, M., & Abbas, O. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27036 · Cited by 112
Cavanaugh, A. M., Fortier, S., Lewis, P., Arora, V., Johnson, M., George, K., Tobias, J., Lunn, S. M., Miller, T., Thoroughman, D. A., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7017e2 · Cited by 120
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.